PharmaCyte Biotech Inc., a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology. Today, Cell-in-a-Box®, announced that the original cytochrome P450 expressing cells from PharmaCyte’s Master Cell Bank (MCB) manufactured by Eurofins Lancaster Laboratories had survived three years of storage in a vapor phase of liquid nitrogen.
This research is in addition to and distinct from the CypCaps product’s previously positive stability study test results the following storage at -80C for various periods. The property that causes the activation of low dose ifosfamide in patients destroying their malignant tumors is known as enzymatic activity. As a result, having high enzymatic activity is a direct indicator of a cell’s efficacy.
This technology is being used as a foundation for developing medicines for a variety of cancers and diabetes. Encapsulating genetically engineered human cells that convert an inactive chemotherapeutic drug into its active or “cancer-killing” form is how PharmaCyte’s cancer therapy works.These encapsulated cells are implanted in the blood supply to the patient’s tumor as close to the tumor site as possible in pancreatic cancer. The chemotherapeutic prodrug ifosfamide, ordinarily activated in the liver, is given intravenously at one-third the regular dose once the device is placed. The ifosfamide is delivered to the site where the circulatory system has implanted the encapsulated cells.